Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

BACKGROUND: Sunitinib malate (SUTENT(®)) is an oral, multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib-resistant or – intolerant GIST. The purpose of this study was to explore potential biomarkers of sunitinib pharmacological activity...

Descripción completa

Detalles Bibliográficos
Autores principales: DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939830/
https://www.ncbi.nlm.nih.gov/pubmed/17605814
http://dx.doi.org/10.1186/1479-5876-5-32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939830/
https://www.ncbi.nlm.nih.gov/pubmed/17605814
http://dx.doi.org/10.1186/1479-5876-5-32

Ejemplares similares